Allogene Therapeutics

ALLONasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$380.040 M

$1.10 -7.56%

Close of 6 Nov 2026

As of 6 Nov 2026, Allogene Therapeutics (ALLO) has a market capitalization of $380.0M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$190.9M

Loss-making

Shares outstanding

346,467,307

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#68Editas MedicineEDIT$390.9M
#69Tectonic TherapeuticTECX$382.0M
#70Allogene TherapeuticsALLO$380.0M
#71TevogenTVGN$377.4M
#72C4 TherapeuticsCCCC$362.3M

What if Allogene Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$81,729.72

Per share 74,300× higher

Bitcoin $1.53T

$4,422.25

Per share 4,020× higher

Apple $5.02T

$14,517.84

Per share 13,198× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Allogene Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.